HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and maintains a $16 price target.
June 13, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Panbela Therapeutics and maintains a $16 price target.
The Buy rating and maintained $16 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Panbela Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100